Biotech-Focused Fund Adds Million: Immunome Bet Surges
A leading biotech-focused fund just boosted its Immunome position by a material amount as the stock surged. This arti...
This article outlines scenarios where target date funds may be preferable to index funds in a 401(k), focusing on simplicity and risk management.
26,105 articlesA leading biotech-focused fund just boosted its Immunome position by a material amount as the stock surged. This arti...
A high-profile market commentator signals a pullback may be on the horizon, even as AI-driven gains keep major indice...
Investors are watching silver surge with remarkable momentum. This guide shows how the silver 160% year here trend ha...
After a short three-day drift, major averages regained their footing on Thursday. The Dow, S&P 500, and NASDAQ logged...
Rising buzz that Elon Musk could reach trillionaire status clashes with Tesla's 2026 stock slump. This report breaks ...
As Turning Point Brands rode a wave of rising oral nicotine sales, one fund made a bold move: trimming a multi-millio...
SpaceX IPO buzz is electric. Here are the two simplest routes retail investors can use to access shares at the IPO pr...
Starting with $1,000 doesn't mean you have to settle for small gains. This guide lays out a clear framework to find t...
Investors are spotting a familiar pattern that last showed up in 2020. This piece breaks down what the stock market j...
JEPQ offers a near-9.5% yield by pairing Nasdaq-100 stocks with equity-linked notes. But the unsecured counterparty r...
Fidelity’s zero-fee ETF has quietly tracked broad-market gains for years, delivering competitive returns with no expe...
The Nasdaq may be hovering near a correction, but smart planning helps investors navigate volatility. Here are four e...